Abstract
Backgrounds Traveler’s thrombosis is well-known even among non-professionals as “economy class syndrome.” However, controversial discussions have remained. Clark et al. mentioned no solid evidence in their article “Long-haul travel and venous thrombosis: What is the evidence?” (1). Also, the status of recent COVID-19-related thrombosis research seemed like that of the traveler’s thrombosis. We hypothesized there might be something overlooked behind those strange situations.
Methods Since ordinary review methods (e.g., systematic review or meta-analysis) had already been conducted (2–7), we focused on reviewing a “previously published” “chart.” Also, we developed a novel “review method” for the meta-regression analysis result. We applied those to some previously published and well-known data.
Results We newly found an approximately 28 days cycle of thrombosis onset over several weeks after travel in a figure (Cannegieter et al., PLoS Med. 2006, in the top 25% of all research scored by Altmetric) (8). Also, we found an eighteen-day cycle of thrombosis onset in another chart (Kelman et al., BMJ. 2003, in the top 5% of research) (9). In COVID-19, we newly extracted subgroup patterns in a scatterplot (Troponin T and NT-proBNP) that applied simple linear regression analysis (Guo et al. JAMA Cardiol. 2020, top 5% research) (10). Also, these subgroups have already appeared in the cardiomyopathy study (Budnik et al., Int J Cardiol. 2016) (11).
Conclusions There has been a widespread belief that in-flight environments cause thrombosis. Also, the phenomenon of the onset of thrombosis after over a few weeks to two months since the travel has been explained, such as the development of blood clots occurring on a cabin, but the dislodge of a thrombus occurs after the travel (12). However, from cyclic patterns of thrombosis onset, it is more reasonable to explain that the “travel” and “high-risk period of thrombosis with Oral Contraceptives (OC) use (within three months from starting OC)” coincided with the travel (e.g., honeymoon and starting birth control OC). The influence of the in-flight environment may be less than we had previously thought. Although simple linear regression analysis has been used in studies of cardiovascular biomarkers, including the case of COVID-19, there seems to be a complex scatterplot structure that is unsuitable for simple linear fitting. Considering our findings, in a literature review, a pattern on a chart should be given more paying attention.
What is already known on this topic Strange controversies have remained in thrombosis-related fields (traveler’s and COVID-19-related thrombosis). Traveler’s thrombosis sometimes occurs over two months after leaving the risky in-flight environment. This phenomenon has been explained that the thrombus is formed in a cabin but dislodged after (12). Oral contraceptives (OC) were recognized as aggravating factors (13). COVID-19, although this is the first time humans have faced SARS-Cov-2, there has been a long research history on infectious-associated thrombosis.
What this study adds We hypothesized something might be overlooked and focused on reviewing a “previously published” “chart.” We found thrombosis onset cycles. These findings may imply thrombosis after travel is caused by overlapping the travel period and the initial period of taking OC, which is the high-risk period for thrombosis. In COVID-19 cardiovascular biomarker studies, there seems to be a complex scatterplot structure that is unsuitable for usually used simple linear fitting. In a literature review, a pattern on a chart should be given more paying attention.
Competing Interest Statement
Munekazu Yamakuchi, Kazunori Takenouchi, and Teruto Hashiguchi have completed the Unified Competing Interest form and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. Keiichiro Kimoto has been in charge of external advisor for the Data Strategy Research Institute but received no financial support for this study.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was not required ethical approval because the study used ONLY two types of openly available human data. Firstly, this study performed meta-analyses as secondary analyses. The source of the data was described in the method section. Second, this study analyzed measured values from figures in previous published scientific papers. All the figures were appropriately treated with careful attention to the copyright issues to protect the integrity of the science. The sources of the original articles were described in the figure legend following the copyright holder’s instructions. Also, we submit copyright details in another file to a journal that we submit this manuscript file to explain additional information. This study suggests a new review strategy and meta-analysis method for exploratory data analysis and reports some epidemiological findings. So, there were no applicable guidelines (e.g., Preferred Reporting Items for Systematic reviews and Meta-Analyses, PRISMA). However, this study carefully follows the usage of the statistical analysis method, and the whole process is precisely described in the method details section and Fig. 2. This study was not received financial support from any funding.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Copyright
The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.
Competing interest statement
Munekazu Yamakuchi, Kazunori Takenouchi, and Teruto Hashiguchi have completed the Unified Competing Interest form and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. Keiichiro Kimoto has been in charge of external advisor for the Data Strategy Research Institute but received no financial support for this study.
Classification: Research article
This file includes Abstract, Summary boxes, Main Text, Figures 1 to 7, and Table 1. Also, this article has supporting information that contains supporting figures, tables, method details, and supporting discussions.
We thought submitting our research to a general scientific journal would be appropriate because this manuscript has both importance in medicine and scientific importance. However, we considered comments that we should submit our manuscript to a journal specializing in medicine, and we decided the manuscript to such a journal. So, we revised our manuscript for readers in medical journals, especially the introduction and discussion. Also, we add a conclusion section.
Data Availability
Data availability statement We analyzed clinical data published by other studies (third parties). Used data is identified by indicated information of citation (reference numbers and list of references). The corresponding author responds to inquiries in the case of measured values from published figures requested by reviewers or readers. Code availability statement Correspondence author (KK) can respond to inquiries for the corresponding author’s email address on offering the Python source code and spreadsheet software files for statistical analysis. Also, we have already uploaded our Python programs for the following GitHub repository to keep traceability perfectly. https://github.com/Keiichiro-KIMOTO-Kagoshima-University/Findings_in_Travel-related_Thrombosis_and_COVID-19_Related_Cardiac_Biomarker_Data
